Figure S1-26 (Discovering novel antigenic peptides targeted cervical cancer by profiling HLA-I ligandomes)

Figure S1 HE staining and HLA class I protein expression in PC and CC tissue samples.Figure S2 Venn analysis of the MIPs identified by the customized peptide and Uniprot databases.Figure S3 The frequency of the tumor-associated HLA-I peptides source proteins in 21 CC samples.Figure S4 Pathway and text mining analysis of GPX1.Figure S5 Pathway and text mining analysis of CKAP5.Figure S6 Pathway and text mining analysis of MYO9B.Figure S7 Pathway and text mining analysis of LAMB1.Figure S8 Pathways and text mining analysis of MCM4.Figure S9 Pathway analysis of EIF3D.Figure S10 Pathway analysis of PNKP.Figure S11 B+ y+ ion mass spectral comparison of the synthetic peptides and the naturally presenting peptides.Figure S12 B+ y+ ion mass spectral comparison of the synthetic peptides and the naturally presented peptides.Figure S13 B+ y+ ion mass spectral comparison of the synthetic peptides and the naturally presented peptides.Figure S14 B+ y+ ion mass spectral comparison of the synthetic peptides and the naturally presented peptides.Figure S15 B+ y+ ion mass spectrum comparison of synthetic peptides and naturally presented peptides.Figure S16 B+ y+ ion mass spectrum comparison of synthetic peptides and naturally presented peptides.Figure S17 B+ y+ ion mass spectrum comparison of synthetic peptides and naturally presented peptides.Figure S18 B+ y+ ion mass spectrum comparison of synthetic peptides and naturally presented peptides.Figure S19 B+ y+ ion mass spectrum comparison of synthetic peptides and naturally presented peptides.Figure S20 B+ y+ ion mass spectrum comparison of synthetic peptides and naturally presented peptides.Figure S21 B+ y+ ion mass spectrum comparison of synthetic peptides and naturally presented peptides.Figure S22 B+ y+ ion mass spectrum comparison of synthetic peptides and naturally presented peptides.Figure S23 B+ y+ ion mass spectrum comparison of synthetic peptides.Figure S24 Examples of the CC-specific peptides that were evaluated in IFN-γ ELISPOTs using PBMCs obtained from a healthy donor.Figure S25 CC-specific peptides directly induced IFN-γ secretion in vitro.Figure S26 Ex vivo CD8+ T cell responses against the CC-specific peptides and PD-1 blockade the peripheral in partial CC patients.